The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis -HIV-1 coinfection

AIDS

Volumn 23, Issue 7, 2009, Pages 865-867

  Armstrong James, Darius ^a,b   Menon Johansson, Anatole ^a   Pozniak, Anton ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LUNG TUBERCULOSIS; MALE; MILIARY TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; ANTIVIRAL RESISTANCE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; VIROLOGY;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 67649644704     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283294a04     Document Type: Article

References (9)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021.
2. Floyd K, Wilkinson D. Tuberculosis in the HIV/AIDS era: interactions, impacts and solutions. AIDS Anal Afr 1997;7:5-7.
3. Pepper DJ, Meintjes GA, Mcllleron H, Wilkinson RJ. Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discov Today 2007;12:980-989.
4. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530539.
5. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-850.
6. Dart Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/ lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 2008; 13: 6-16.
7. Lalloo UG, Pillay S. Managing tuberculosis and HIV in sub-Sahara Africa. Curr HIV/AIDS Rep 2008;5:132-139.
8. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008;5:e158.
9. Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, et al. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Antivir Ther 2006;11:827-830.